DNA
Ginkgo Bioworks Holdings, Inc.
NYSE · Healthcare · Biotechnology · US
$7.88
+0.51%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.58
- Revenue estimate
- $21.6M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.75
- EPS estimate
- -$0.90
- Revenue actual
- $20.2M
- Revenue estimate
- $24.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +4.3%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Sell
- Price target
- $7.00
- PT range
- $5.00 – $9.00
- Analysts
- 2
0 Buy1 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.90 | -$0.75 | Beat 16.20% | $20.2M |
| May 7, 2026 | -$1.21 | -$1.28 | Miss -5.68% | $19.5M |
| Nov 6, 2025 | -$1.24 | -$1.45 | Miss -16.94% | $38.8M |
| Aug 7, 2025 | -$1.44 | -$1.10 | Beat 23.61% | $49.6M |
| Aug 8, 2024 | -$3.20 | -$3.20 | In line | $56.2M |
| May 9, 2024 | -$3.20 | -$3.20 | In line | $37.9M |
| Feb 29, 2024 | -$3.60 | -$3.60 | In line | $34.8M |
| Mar 1, 2023 | -$12 | -$1.60 | Beat 86.67% | $98.3M |
| Nov 14, 2022 | -$10 | -$16 | Miss -60.00% | $66.4M |
| Aug 15, 2022 | -$2.00 | -$16 | Miss -720.00% | $144.6M |
| May 16, 2022 | -$1.60 | -$2.00 | Miss -25.00% | $168.4M |
| Nov 15, 2021 | -$1.60 | -$2.80 | Miss -75.00% | $77.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026